<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>VTRS on FinanClub</title>
    <link>https://finan.club/tags/vtrs/</link>
    <description>Recent content in VTRS on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 06 Aug 2023 10:25:27 +0000</lastBuildDate><atom:link href="https://finan.club/tags/vtrs/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>1076 VTRS</title>
      <link>https://finan.club/us/vtrs/</link>
      <pubDate>Sun, 06 Aug 2023 10:25:27 +0000</pubDate>
      
      <guid>https://finan.club/us/vtrs/</guid>
      <description>score:1076
Chances: Viatris has the potential to be a great dividend holding due to its decently high dividend yield, stable line of business, and disruption-resistant business model. The launch of Breyna™, the first generic version of AstraZeneca&amp;rsquo;s Symbicort®, could potentially contribute to Viatris&amp;rsquo; revenue and growth in the healthcare sector.</description>
    </item>
    
  </channel>
</rss>
